Image_7_Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.tif
Chimeric antigen receptor T (CAR-T) cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascular diseases and arthritis. Thus, these patients frequently receive concomitant medications that include nonsteroidal anti-inflammatory drugs (NSAIDs) like cyclooxygenase (COX) inhibitors. Celecoxib, a selective COX-2 inhibitor, and aspirin, a non-selective COX-1 and COX-2 inhibitor, are being used as anti-inflammatory, analgesic and anti-pyretic drugs. In addition, several studies have also focused on the anti-neoplastic properties of COX-inhibitors. As the influence of COX-inhibitors on CD19.CAR-T cells is still unknown, we investigated the effect of celecoxib and aspirin on the quantity and quality of CD19.CAR-T cells at different concentrations with special regard to cytotoxicity, activation, cytokine release, proliferation and exhaustion. A significant effect on CAR-T cells could be observed for 0.1 mmol/L of celecoxib and for 4 mmol/L of aspirin. At these concentrations, we found that both COX-inhibitors could induce intrinsic apoptosis of CD19.CAR-T cells showing a significant reduction in the ratio of JC-10 red to JC-10 green CAR-T cells from 6.46 ± 7.03 (mean ± SD) to 1.76 ± 0.67 by celecoxib and to 4.41 ± 0.32 by aspirin, respectively. Additionally, the ratios of JC-10 red to JC-10 green Daudi cells were also decreased from 3.41 ± 0.30 to 0.77 ± 0.06 by celecoxib and to 1.26 ± 0.04 by aspirin, respectively. Although the cytokine release by CD19.CAR-T cells upon activation was not hampered by both COX-inhibitors, activation and proliferation of CAR-T cells were significantly inhibited via diminishing the NF-ĸB signaling pathway by a significant down-regulation of expression of CD27 on CD4+ and CD8+ CAR-T cells, followed by a clear decrease of phosphorylated NF-ĸB p65 in both CD4+ and CD8+ CAR-T cells by a factor of 1.8. Of note, COX-inhibitors hampered expansion and induced exhaustion of CAR-T cells in an antigen stress assay. Collectively, our findings indicate that the use of COX-inhibitors is a double-edged sword that not only induces apoptosis in tumor cells but also impairs the quantity and quality of CAR-T cells. Therefore, COX-inhibitors should be used with caution in patients with B cell lymphoma under CAR-T cell therapy.
History
References
- https://doi.org//10.1056/NEJMoa1709866
- https://doi.org//10.1200/JCO.2017.72.8519
- https://doi.org//10.1016/j.ymthe.2017.07.004
- https://doi.org//10.1056/NEJMoa1707447
- https://doi.org//10.1056/NEJMoa1708566
- https://doi.org//10.2174/1389450119666180803121737
- https://doi.org//10.1158/1078-0432.CCR-18-0426
- https://doi.org//10.1016/j.jcyt.2019.02.013
- https://doi.org//10.3389/fimmu.2017.01956
- https://doi.org//10.1089/hum.2017.237
- https://doi.org//10.1038/80877
- https://doi.org//10.1038/s41551-018-0235-9
- https://doi.org//10.1056/NEJMoa1407222
- https://doi.org//10.1016/S0140-6736%2814%2961403-3
- https://doi.org//10.1056/NEJMoa1709919
- https://doi.org//10.1111/j.1349-7006.2004.tb02200.x
- https://doi.org//10.1056/NEJMoa1707447
- https://doi.org//10.1074/jbc.M110676200
- https://doi.org//10.1038/23948
- https://doi.org//10.3892/ijo.2011.1304
- https://doi.org//10.1007/s00018-008-7511-x
- https://doi.org//10.3892/ol.2018.8377
- https://doi.org//10.1016/j.bcp.2009.07.021
- https://doi.org//10.3390/jcm8020200
- https://doi.org//10.1002/cyto.a.21010
- https://doi.org//10.1111/j.1600-065X.2012.01095.x
- https://doi.org//10.1111/j.1600-065X.2011.01092.x
- https://doi.org//10.1186/1752-0509-5-115
- https://doi.org//10.1038/nri1184
- https://doi.org//10.2147/JIR.S140188
- https://doi.org//10.1084/jem.20030916
- https://doi.org//10.2217/imt.15.32
- https://doi.org//10.1091/mbc.e10-06-0556
- https://doi.org//10.4049/jimmunol.1000159
- https://doi.org//10.1093/intimm/dxm033
- https://doi.org//10.1038/ni.2035
- https://doi.org//10.1002/j.1552-4604.1987.tb03019.x
- https://doi.org//10.1016/0378-4347%2895%2900464-5
- https://doi.org//10.1016/j.biopha.2020.110389
- https://doi.org//10.1056/NEJM200006293422603
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity